🌟 Stock of the Week: Divi’s Laboratories Ltd. (NSE: DIVISLAB)

Hello ,

In a market where pharma has quietly been regaining strength, Divi’s Laboratories continues to shine as one of India’s most formidable API exporters - a true example of quality, scale, and consistency. With a near debt-free balance sheet, global leadership in select APIs, and strong margins even through cycles, Divi’s stands as a resilient compounder in the Indian pharma space.

🌟 Stock of the Week: Divi’s Laboratories Ltd. (NSE: DIVISLAB)
📅 Featured in: Multi Factor – May Cohort & many other GoalFi baskets
📈 +17.9% YoY Sales Growth | ROE: 15.4% | OPM: 31.8%

🏢 Company Overview

Incorporated in 1990, Divi’s Laboratories Ltd. is one of India’s leading manufacturers and exporters of Active Pharmaceutical Ingredients (APIs), Intermediates, and Nutraceutical ingredients. The company caters to global pharmaceutical and nutraceutical industries, exporting to over 100 countries, with ~90% of revenue derived from exports.

🧪 Business Segments

• Generic APIs:
  Manufactures 30+ large-volume APIs in therapeutic categories such as anti-depressants, anti-cancer, and anti-inflammatory drugs. Produces 10–1000 tons annually, serving global pharma majors.

• Custom Synthesis:
  Provides contract manufacturing and custom synthesis of APIs and intermediates for multinational pharmaceutical companies.

• Nutraceuticals:
  Operates a state-of-the-art unit in Visakhapatnam, producing carotenoids and other active ingredients for major food and dietary supplement brands worldwide.

⚙️ Manufacturing Footprint

• R&D: 3 centers with 6 multi-purpose manufacturing facilities in Telangana and Andhra Pradesh.

• Capacity: Over 14,500 m³ reactor capacity, one of the largest globally.

• Regulatory Strength: 30+ cGMP audits and 2000+ quality audits by global clients.

🌍 Global Presence

Subsidiaries in New Jersey (USA) and Basel (Switzerland) for marketing and client support.

Geographical Split (FY22):

• North America – 44%

• Europe – 33%

• Asia – 9%

• ROW – 4%

• India – 10%

💰 Financial Snapshot

Quarterly Performance (₹ Cr)

Annual Snapshot (₹ Cr)

Key Valuation Metrics (as of Oct 10, 2025)

⚖️ Pros & Cons

Pros:

• Virtually debt-free with consistent cash generation

• Strong export-led model with 90%+ international sales

• Consistent dividend payout and robust R&D framework

Cons:

• Stock trades at a steep valuation of 11.5x book value

• Moderate long-term sales CAGR of 12% over the last decade

📈 Shareholding (June 2025)

💡 GoalFi View

Divi’s Laboratories exemplifies the “quality at scale” narrative - combining clean governance, strong balance sheet, and global trust in Indian APIs. While valuations are rich, its consistent margins, export-led earnings, and leadership in niche molecules justify long-term compounding potential.

Divi’s remains a defensive compounder with cyclical tailwinds likely to emerge as global pharma demand revives - making it a steady anchor in the GoalFi portfolio.

Stay calm, stay invested, and let compounding do the magic. ✨

📩 Reach us via chat.goalfi.app ✉ Email: [email protected]

📢 GoalFi Announcement

We’re expanding our GoalFi WhatsApp Community for our valued subscribers!

If you’re a subscriber but not yet part of the community, we’d be happy to welcome you in.

Get access to:
✔️ Daily research updates
✔️ Market insights
✔️ Live alerts
✔️ Direct analyst communication

📩 To join, simply message us at 👉 chat.goalfi.app

Let’s build smarter investing habits, together.
https://goalfiresearch.smallcase.com

We hope this update helps you stay informed and empowered in your investment journey. Feel free to reach out if you have any questions or need personalized advice.

Best Regards,
Team GoalFi

Disclosures: https://goalfiresearch.smallcase.com/#disclosures

Disclaimer: This newsletter is intended solely for educational and informational use. It does not constitute financial advice or serve as a promotional message.